UA73100C2 - Method for inhibiting proliferation of cancer cells by administering growth hormone releasing compound or its antagonist - Google Patents
Method for inhibiting proliferation of cancer cells by administering growth hormone releasing compound or its antagonist Download PDFInfo
- Publication number
- UA73100C2 UA73100C2 UA2001064044A UA2001064044A UA73100C2 UA 73100 C2 UA73100 C2 UA 73100C2 UA 2001064044 A UA2001064044 A UA 2001064044A UA 2001064044 A UA2001064044 A UA 2001064044A UA 73100 C2 UA73100 C2 UA 73100C2
- Authority
- UA
- Ukraine
- Prior art keywords
- mgr
- ttr
- aia
- rne
- niz
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 61
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 17
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 16
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 16
- 239000005557 antagonist Substances 0.000 title claims abstract description 16
- 239000000122 growth hormone Substances 0.000 title claims abstract description 16
- 230000035755 proliferation Effects 0.000 title claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 title claims description 3
- 201000011510 cancer Diseases 0.000 title description 4
- 210000001685 thyroid gland Anatomy 0.000 claims abstract description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract description 3
- 210000001519 tissue Anatomy 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims description 5
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims description 4
- 210000005075 mammary gland Anatomy 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- -1 bicyclic compound Chemical class 0.000 claims 1
- 201000006385 lung benign neoplasm Diseases 0.000 claims 1
- 231100000590 oncogenic Toxicity 0.000 claims 1
- 230000002246 oncogenic effect Effects 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 241000124008 Mammalia Species 0.000 abstract description 5
- 210000004072 lung Anatomy 0.000 abstract description 5
- 206010006187 Breast cancer Diseases 0.000 abstract description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract description 2
- 208000037841 lung tumor Diseases 0.000 abstract description 2
- CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 abstract 1
- 208000013076 thyroid tumor Diseases 0.000 abstract 1
- 231100000588 tumorigenic Toxicity 0.000 abstract 1
- 230000000381 tumorigenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 13
- 108010070965 hexarelin Proteins 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 11
- 230000027455 binding Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 201000005296 lung carcinoma Diseases 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- 102000005157 Somatostatin Human genes 0.000 description 4
- 108010056088 Somatostatin Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 4
- 229960000553 somatostatin Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010082883 EP80317 Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
- 101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AVKNGPAMCBSNSO-UHFFFAOYSA-N cyclohexylmethanamine Chemical compound NCC1CCCCC1 AVKNGPAMCBSNSO-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000012333 histopathological diagnosis Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000045360 human SDHB Human genes 0.000 description 1
- 229960002050 hydrofluoric acid Drugs 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- MDKCOSRPPDDOPZ-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepin-2-amine Chemical compound N1=CC=CC=C2C3=NC(N)=CC3=CC=C21 MDKCOSRPPDDOPZ-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/192,406 US6124263A (en) | 1998-11-16 | 1998-11-16 | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| PCT/EP1999/008662 WO2000029011A1 (en) | 1998-11-16 | 1999-11-11 | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73100C2 true UA73100C2 (en) | 2005-06-15 |
Family
ID=22709509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001064044A UA73100C2 (en) | 1998-11-16 | 1999-11-11 | Method for inhibiting proliferation of cancer cells by administering growth hormone releasing compound or its antagonist |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6124263A (zh) |
| EP (1) | EP1131083B1 (zh) |
| JP (1) | JP2002529512A (zh) |
| KR (1) | KR100704138B1 (zh) |
| CN (3) | CN1277840C (zh) |
| AR (1) | AR021286A1 (zh) |
| AT (1) | ATE258062T1 (zh) |
| BG (1) | BG105572A (zh) |
| BR (1) | BR9915390A (zh) |
| CA (1) | CA2350914A1 (zh) |
| CO (1) | CO5140111A1 (zh) |
| CZ (1) | CZ20011577A3 (zh) |
| DE (1) | DE69914365T2 (zh) |
| DK (1) | DK1131083T3 (zh) |
| ES (1) | ES2212650T3 (zh) |
| HK (1) | HK1040934A1 (zh) |
| HU (1) | HUP0104374A3 (zh) |
| IL (1) | IL142858A0 (zh) |
| MX (1) | MXPA01004689A (zh) |
| NO (1) | NO20012367L (zh) |
| NZ (1) | NZ511280A (zh) |
| PL (1) | PL347659A1 (zh) |
| PT (1) | PT1131083E (zh) |
| RU (1) | RU2240133C2 (zh) |
| SK (1) | SK6352001A3 (zh) |
| TR (1) | TR200101350T2 (zh) |
| TW (2) | TWI263642B (zh) |
| UA (1) | UA73100C2 (zh) |
| WO (1) | WO2000029011A1 (zh) |
| ZA (1) | ZA200103182B (zh) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211156B1 (en) * | 1999-11-10 | 2001-04-03 | Asta Medica A.G. | Peptides for treatment of erectile dysfunction |
| CU23157A1 (es) * | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
| DE10112882A1 (de) * | 2001-03-15 | 2002-09-19 | Max Delbrueck Centrum | Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden Tumoren |
| US20040157227A1 (en) * | 2001-05-10 | 2004-08-12 | Chopin Lisa Kerstin | Reproductive cancer diagnosis and therapy |
| EP1312363A1 (en) * | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
| TWI331922B (en) | 2002-08-09 | 2010-10-21 | Ipsen Pharma Sas | Growth hormone releasing peptides |
| WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| US20050164952A1 (en) * | 2004-01-23 | 2005-07-28 | Vital Pharmaceuticals, Inc. | Delivery system for growth hormone releasing peptides |
| EP2021015A2 (en) * | 2006-04-28 | 2009-02-11 | The Administrators Of The Tulane Educational Fund | Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof |
| NZ576470A (en) | 2006-09-27 | 2012-09-28 | Ipsen Pharma Sas | Analogs of ghrelin substituted at the n-terminal |
| CN101686966A (zh) * | 2007-02-13 | 2010-03-31 | 赫尔辛医疗（美国）有限公司 | 使用生长激素促分泌素治疗细胞增生疾病的方法 |
| WO2010118309A2 (en) * | 2009-04-10 | 2010-10-14 | Board Of Regents, The University Of Texas System | Inhibitors of stat3 and uses thereof |
| US9724381B2 (en) | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
| IT1399610B1 (it) * | 2010-01-28 | 2013-04-26 | Univ Milano Bicocca | Uso di agonisti e antagonisti dei recettori per i growth hormone secretagogues per la prevenzione e il trattamento di convulsioni ed epilessia |
| EP3920961A4 (en) | 2019-02-08 | 2022-12-14 | United States Government as represented by the Department of Veterans Affairs | GROWTH HORMONE RELEASING HORMONE ANTAGONISTS AND THEIR USES |
| WO2021011874A1 (en) * | 2019-07-18 | 2021-01-21 | University Of Miami | Ghrh antagonists for use in a method of treating sarcoidosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2882679B2 (ja) * | 1989-04-26 | 1999-04-12 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | 線状ソマトスタチン類似体 |
| IT1240643B (it) * | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano |
| GB2244063A (en) * | 1990-05-15 | 1991-11-20 | Exxon Research Engineering Co | Grease composition containing inorganic compounds |
| RO117259B1 (ro) * | 1993-08-09 | 2001-12-28 | Biomeasure Inc. | Derivaţi peptidici, terapeutici |
| US5550212A (en) * | 1993-12-17 | 1996-08-27 | The Administrators Of The Tulane Educational Fund | Analogues of hGH-RH(1-29)NH2 having antagonistic activity |
| US5807985A (en) * | 1996-06-11 | 1998-09-15 | Deghenghi; Romano | Oligopeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone |
| US6063796A (en) * | 1997-04-04 | 2000-05-16 | Merck & Co., Inc. | Somatostatin agonists |
-
1998
- 1998-11-16 US US09/192,406 patent/US6124263A/en not_active Expired - Fee Related
-
1999
- 1999-10-28 CO CO99068206A patent/CO5140111A1/es unknown
- 1999-11-11 DK DK99955974T patent/DK1131083T3/da active
- 1999-11-11 HU HU0104374A patent/HUP0104374A3/hu unknown
- 1999-11-11 CN CNB200410045995XA patent/CN1277840C/zh not_active Expired - Fee Related
- 1999-11-11 WO PCT/EP1999/008662 patent/WO2000029011A1/en active IP Right Grant
- 1999-11-11 CN CNB2006100998244A patent/CN100368014C/zh not_active Expired - Fee Related
- 1999-11-11 BR BR9915390-4A patent/BR9915390A/pt not_active IP Right Cessation
- 1999-11-11 CZ CZ20011577A patent/CZ20011577A3/cs unknown
- 1999-11-11 KR KR1020017006163A patent/KR100704138B1/ko not_active IP Right Cessation
- 1999-11-11 CA CA002350914A patent/CA2350914A1/en not_active Abandoned
- 1999-11-11 CN CNB998133612A patent/CN1200726C/zh not_active Expired - Fee Related
- 1999-11-11 PL PL99347659A patent/PL347659A1/xx unknown
- 1999-11-11 TR TR2001/01350T patent/TR200101350T2/xx unknown
- 1999-11-11 RU RU2001116722/14A patent/RU2240133C2/ru not_active IP Right Cessation
- 1999-11-11 IL IL14285899A patent/IL142858A0/xx unknown
- 1999-11-11 DE DE69914365T patent/DE69914365T2/de not_active Expired - Fee Related
- 1999-11-11 EP EP99955974A patent/EP1131083B1/en not_active Expired - Lifetime
- 1999-11-11 MX MXPA01004689A patent/MXPA01004689A/es not_active IP Right Cessation
- 1999-11-11 UA UA2001064044A patent/UA73100C2/uk unknown
- 1999-11-11 NZ NZ511280A patent/NZ511280A/xx unknown
- 1999-11-11 JP JP2000582057A patent/JP2002529512A/ja active Pending
- 1999-11-11 ES ES99955974T patent/ES2212650T3/es not_active Expired - Lifetime
- 1999-11-11 SK SK635-2001A patent/SK6352001A3/sk unknown
- 1999-11-11 PT PT99955974T patent/PT1131083E/pt unknown
- 1999-11-11 AT AT99955974T patent/ATE258062T1/de not_active IP Right Cessation
- 1999-11-16 AR ARP990105814A patent/AR021286A1/es unknown
- 1999-11-30 TW TW094111886A patent/TWI263642B/zh not_active IP Right Cessation
- 1999-11-30 TW TW088117984A patent/TWI237565B/zh not_active IP Right Cessation
-
2001
- 2001-04-19 ZA ZA200103182A patent/ZA200103182B/en unknown
- 2001-05-14 NO NO20012367A patent/NO20012367L/no not_active Application Discontinuation
- 2001-06-07 BG BG105572A patent/BG105572A/xx unknown
-
2002
- 2002-04-12 HK HK02102769.3A patent/HK1040934A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA73100C2 (en) | Method for inhibiting proliferation of cancer cells by administering growth hormone releasing compound or its antagonist | |
| US8377865B2 (en) | Growth hormone releasing peptides | |
| US9381225B2 (en) | Methods of protecting against apoptosis using lipopeptides | |
| Woll et al. | A neuropeptide antagonist that inhabits the growth of small cell lung cancer in vitro | |
| EP0644772B1 (en) | Opioid peptides | |
| US20100168038A1 (en) | Use of compounds in combination with gamma-irradiation for the treatment of cancer | |
| TW575582B (en) | Somatostatin antagonists | |
| AU768516B2 (en) | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists | |
| US12024515B2 (en) | Kifunensine derivatives | |
| Tsutsumi et al. | Biphasic effects of suramin on 125 I-epidermal growth factor binding to human meningiomas | |
| Bowers | GHRP historical perspective: basic and clinical | |
| Muller | Insights from growth hormone receptor blockade | |
| Patchett et al. | The design of peptidomimetic growth hormone secretagogues | |
| AU2007202409B2 (en) | Growth hormone releasing peptides | |
| Pleasanton et al. | Aurrecoechea et al.(43) Pub. Date: Jul. 20, 2006 |